Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings.
Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is a next-generation oral cardiac myosin inhibitor licensed from China's Hengrui Pharmaceuticals designed to treat both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Braveheart plans to initiate a global Phase 3 trial in obstructive HCM in the 2H26, followed by a Phase 3 trial in non-obstructive HCM in the 1H27. It finished the week up 67%.
Pain relief biotech Latigo Therapeutics (LTGO) priced its upsized IPO at the top of the range, raising $346 million at a $1.3 billion market cap. Its lead candidate, LTG-001, is an oral Nav1.8 inhibitor for moderate to severe acute pain, including postoperative pain. A placebo-controlled Phase 3 bunionectomy trial and an open-label Phase 3 safety trial are planned for the 2H26, with topline results expected in the 2H27. Latigo therapeutics finished the week up 1%.
Immune system diseases-focused biotech Attovia Therapeutics (ATTO) priced its previously upsized IPO at the high end to raise $289 million at a $767 million market cap. Attovia is developing biologic therapies for immune-mediated diseases using its ATTOBODY platform to create next-generation antibody therapeutics targeting validated immune pathways. Its lead candidate, ATTO-1310, targets IL-31 for chronic pruritus and high-itch atopic dermatitis. It completed Phase 1 dosing in healthy volunteers and patients in the 1Q26, with a Phase 2 trial planned for the 1H27. Attovia Therapeutics finished the week up 19%.
Cancer biotech BlossomHill Therapeutics (BLSM) priced its upsized IPO at the midpoint to raise $150 million at a $503 million market cap. Its lead program, BH-30643, is currently in a global Phase 1/2 trial for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). It plans to seek an end-of-Phase 1 meeting with the FDA in the 4Q26 to discuss recommended Phase 2 dosing and a potential accelerated approval pathway for certain patients. Blossomhill Therapeutics finished the week flat.
California-based River City Bank (RCBC) priced its downsized IPO below the range to raise $122 million at a $637 million market cap. Founded in 1973, River City Bank is a commercial bank serving businesses and real estate investors across Northern California through a relationship-focused banking model. Its commercial real estate lending franchise accounted for roughly 90% of its loan portfolio as of June 30, 2026. River City has also developed a niche serving California Community Choice Aggregator entities, although the resulting deposit base is fairly concentrated. It finished the week up 4%.
Latin American ticket platform Ticketplus (TP) priced its US IPO at the bottom of the range to raise $15 million at a $101 million market cap. Ticketplus provides a full-stack event platform for the live entertainment industry in Latin America. The platform covers the end-to-end event lifecycle, including discovery, primary ticketing, access control, payment processing, analytics, and post-event reporting, and serves promoters, venues, sports organizations, and ticketing companies. Ticketplus finished the week down 13%.
Five SPACs also priced. Pinnacle Acquisition (PNAQ.U) raised $200 million to target commercial and consumer finance businesses. BOA Acquisition II (THEOU) raised $125 million to target real estate and infrastructure. ARC Group Securities I (FJDIU), led by ARC Group executives, raised $105 million. OceanLight Acquisition (OCLTU) raised $100 million to target large underpenetrated markets. TCGX Acquisition (TCGX), formed by TCGX executives, raised $75 million to target healthcare in Asia.
| 11 IPOs During the Week of August 3rd, 2026 | |||||
|---|---|---|---|---|---|
| Issuer Business | Deal Size | Market Cap at IPO | Price vs. Midpoint | First Day Return | Return at 08/07 |
| Braveheart Bio (BRVE) | $383M | $1,604M | 13% | +66% | +67% |
| Phase 3-ready biotech developing oral small molecules for cardiovascular diseases. | |||||
| TCGX Acquisition (TCGX) | $75M | $99M | 0% | +8% | +27% |
| Blank check company formed by TCGX executives targeting healthcare in Asia. | |||||
| Attovia Therapeutics (ATTO) | $289M | $767M | 6% | +29% | +19% |
| Phase 1 biotech developing biotherapeutics for immune-mediated diseases. | |||||
| River City Bank (RCBC) | $122M | $637M | -9% | +4% | +4% |
| California-based commercial bank. | |||||
| Latigo Biotherapeutics (LTGO) | $346M | $1,285M | 6% | +1% | +1% |
| Phase 3-ready biotech developing non-opioid therapies for acute and chronic pain. | |||||
| BOA Acquisition II (THEOU) | $125M | $181M | 0% | +1% | +1% |
| Blank check company targeting real estate and infrastructure. | |||||
| BlossomHill Therapeutics (BLSM) | $150M | $503M | 0% | +0% | +0% |
| Phase 2-ready biotech developing oral small molecule cancer therapies. | |||||
| OceanLight Acquisition (OCLT.U) | $100M | $147M | 0% | +0% | +0% |
| Blank check company led by Ping Zhang targeting large underpenetrated markets. | |||||
| Pinnacle Acquisition (PNAQ.U) | $200M | $252M | 0% | +0% | +0% |
| Blank check company targeting commercial and consumer finance businesses. | |||||
| ARC Group Securities I (FJDIU) | $105M | $156M | 0% | +0% | +0% |
| Blank check company led by ARC Group executives. | |||||
| Ticketplus (TP) | $15M | $101M | -43% | -13% | -13% |
| Latin American live event ticket marketplace and event software provider. | |||||
Sign up for a free trial of our premium platform, IPO Pro. To get our IPO calendar in your inbox, register here.
Two IPOs submitted initial filings this week. Hong Kong-based fit-out provider Zensitive Holding (ZENS.RC) filed to raise $25 million at a $63 million market cap. HydroThermal Reactor power plant developer KiNRG (KINR.RC) filed to raise $17 million at a $299 million market cap.
Eight SPACs submitted initial filings this week. Gravity Acquisition (GVACU) filed to raise $250 million to target businesses in North America, Europe, and Asia. GX Acquisition III (GXTRU) filed to raise $200 million to target advanced computing. Southport Acquisition II (PORT.U) filed to raise $200 million to target the AI industry. 1776 Acquisition (SVSXU) filed to raise $150 million to target technology-enabled businesses. Danneskjold and Galt Acquisition (CPLMU) filed to raise $150 million to target fintech and AI. Luminous Acquisition (LUMIU), led by an executive from ARC Group, filed to raise $105 million. Lucens Capital Acquisition I (LCNS.U) filed to raise $100 million to target firms in Argentina. Rainier Acquisition (RNAQU) filed to raise $75 million to target life sciences.
| 10 Filings During the Week of August 3rd, 2026 | |||
|---|---|---|---|
| Issuer Business | Deal Size | Sector | Lead Underwriter |
| Danneskjold and Galt Acq. (CPLMU) | $150M | SPAC | Cohen & Company |
| Blank check company targeting fintech and AI. | |||
| KiNRG (KINR.RC) | $17M | Utilities | R. F. Lafferty |
| HydroThermal Reactor power plant developer with data center construction operations. | |||
| Lucens Capital Acq. I (LCNS.U) | $100M | SPAC | EarlyBird |
| Blank check company formed by Lucens Capital targeting firms in Argentina. | |||
| Southport Acquisition II (PORT.U) | $200M | SPAC | Cohen & Company |
| Blank check company led by TVC Capital's Jeb Spencer targeting the AI industry. | |||
| Zensitive (ZENS.RC) | $25M | Industrials | Pacific Century |
| Hong Kong-based fit-out services provider for residential and commercial properties. | |||
| Rainier Acquisition (RNAQU) | $75M | SPAC | Chardan |
| Blank check company target life sciences. | |||
| Gravity Acquisition (GVACU) | $250M | SPAC | Maxim |
| Blank check company targeting North America, Europe, and Asia. | |||
| Luminous Acquisition (LUMIU) | $105M | SPAC | Arc Group Securities |
| Blank check company lead by an executive from ARC Group. | |||
| 1776 Acquisition (SVSXU) | $150M | SPAC | Clear Street |
| Blank check company targeting technology-enabled businesses. | |||
| GX Acquisition III (GXTRU) | $200M | SPAC | Cohen & Company |
| Blank check company backed by Trimaran Capital targeting advanced computing. | |||
Sign up for a free trial of our premium platform, IPO Pro. To get our IPO calendar in your inbox, register here.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 8/6/2026, the Renaissance IPO Index was up 18.8% year-to-date, while the S&P 500 was up 13.4%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Astera Labs (ALAB) and CoreWeave (CRWV). The Renaissance International IPO Index was up 40.0% year-to-date, while the ACWX was up 15.7%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Galderma and CATL.
